Adenocarcinoma, Papillary × 1 year × Clear all
NCT02978625 2026-03-18

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA